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Purpose
The aim of this study was to evaluate the role of radiotherapy (RT) in the management of
Ewing sarcoma family tumors (ESFT). 
Materials and Methods
Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988
to 2012. Primary tumor size was ! 8 cm in 33 patients. Surgery, RT, and combined surgery
with RT were applied in 37, 15, and 33 patients, respectively. 
Results
Median follow-up was 43.8 months. Forty-three patients (47.3%) showed recurrence or 
progressive disease. Twelve patients (13.2%) showed local failure after initial treatment.
Thirty-nine patients (42.9%) experienced distant metastases. The 5-year overall survival
(OS), progression-free survival, and local control (LC) were 60.5%, 58.2%, and 85.1%, 
respectively. According to treatment, 5-year LC was 64.8% with RT and 90.2% with combined
surgery and RT (p=0.052). Prognostic factors for OS were tumor size (! 8 cm, p < 0.001)
and surgical resection (p < 0.001). In large tumors (! 8 cm), combined surgery and RT 
produced better LC compared to RT (p=0.033). However, in smaller tumors (< 8 cm), RT
without surgery resulted in a similar LC rate as RT with surgery (p=0.374).
Conclusion
RT used for patients with unfavorable risk factors resulted in worse outcome than for 
patients who received surgery. Smaller tumors could be controlled locally with chemotherapy
and RT. For large tumors, combined surgery and RT is needed. Proper selection of local
treatment modality, RT, surgery, or both is crucial in the management of ESFT. 
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Introduction
The Ewing sarcoma family tumors (ESFT) include Ewing
sarcoma, peripheral primitive neuroectodermal tumor
(PNET), and Askin’s tumor of the chest wall [1]. These 
sarcomas are related to and originate from unique mesenchy-
mal stem cells. A common chromosomal translocation that
results in EWS-ETS has been implicated in 80% to 95% of
cases of ESFT [2,3]. 
Current standard treatment is neoadjuvant chemotherapy
followed by local treatment such as surgery, radiotherapy
(RT), or a combination of both modalities [2]. The application
of neoadjuvant chemotherapy increases the possibility of 
surgical resection by shrinking the primary tumor. Doxoru-
bicin, cyclophosphamide, vincristine, and dactinomycin are
known to be effective. A more effective chemotherapy regi-
men including etoposide and ifosfamide was introduced in
2003 [2,4]. Although ESFT are radiosensitive tumors [5] and
RT has been the treatment choice for local treatment in ESFT
[6], the role of resection has increased with an improvement
of surgical technique [7] and there are concerns over second-
ary malignancies and local failures after RT. Surgery has
been chosen rather than RT for “dispensable bones” (e.g.,
fibula, rib, and smaller lesions of the hands or feet) and has
been often considered in young patients, in whom radiation
late effect was expected to be severe [8]. Moreover, the use
of neoadjuvant chemotherapy often decreases tumors [9] and
results in an increase of complete tumor resection rate [10]. 
This study was performed to find the role of RT in the 
multidisciplinary management of patients with ESFT by 
retrospective review. ESFT is especially rare in Asia [11]. We
collected the patients from two large-scale institutions and
could thus analyze a substantial number of Korean ESFT 
patients in this study. This study's findings could provide
valuable clinical information about Asian ESFT patients.
Materials and Methods
1. Patients
Ninety-one patients who were diagnosed with localized
ESFT and treated in Severance Hospital, Yonsei University
Health System, and Samsung Medical Center, Sungkyun-
kwan University School of Medicine between July 1988 and
July 2012 were collected for evaluation. Included pathologic
diagnoses were osseous Ewing’s sarcoma, extraosseous 
(extraskeletal) Ewing’s sarcoma, and peripheral PNET.
Basically, all patients were evaluated by computed tomog-
raphy (CT) scan and the primary tumor size was defined as
the greatest tumor dimension (maximal diameter in axial or
perpendicular plane) in the CT scan. Patients were divided
into two groups by tumor size (< 8 cm vs. ! 8 cm) [12] and
primary tumor size was ! 8 cm in 33 patients. According to
tumor location or extent, magnetic resonance imaging (MRI),
bone scan, and positron emission tomography were 
conducted in 80, 44, and 47 patients, respectively. 
Ages ranged from 1 to 66 years with a median age of 18
years. The sites of primary tumor were as follows: 23 patients
in extremities, 13 in spine or paravertebral regions, 11 in
pelvis, nine in head and skull, and 35 in trunk or other sites
(Table 1). 
Table 1. Patient characteristics (n=91)
Characteristic No. (%)
Age (yr)
0-9 14 (15.4)
10-19 35 (38.5)
20-29 19 (20.9)
30-39 8 (8.8)
40-49 6 (6.6)
50-59 8 (8.8)
60-69 1 (1.1)
Gender
Male 48 (52.7)
Female 43 (47.3)
Site
Extremity 23 (25.3)
Spine or paravertebral lesions 13 (14.3)
Pelvis 11 (12.1)
Head or skull 9 (9.9)
Trunk or others 35 (38.5)
Tumor diameter (cm)
< 8 58 (63.7)
! 8 33 (36.3)
Chemotherapy
Yes 91 (100.0)
With ifosfamide/ectoposide 65 (71.4)
Without ifosfamide/ectoposide 26 (28.6)
No 0 (
Surgical resection
Yes 70 (76.9)
R0 resection 48 (52.7)
R1 resection 8 (8.8)
R2 resection 14 (15.4)
No 21 (23.1)
Radiotherapy
Yes 48 (52.7)
No 43 (47.3)
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2. Treatments
All patients received chemotherapy basically comprised of
a combination of vincristine, dactinomycin, cyclophos-
phamide, and doxorubicin. Etoposide and/or ifosfamide
was added in 65 patients. High-dose chemotherapy with 
peripheral blood stem cell transplantation was applied in 13
patients; among them, 10 patients underwent stem cell trans-
plantation as second-line treatments, especially for distant
failure (n=7). 
As for the local treatment, surgery, RT, and combined 
surgery with RT were performed in 37, 15, and 33 patients,
respectively (Fig. 1). In regard to extent of surgical resection,
R0, R1, and R2 resections were performed in 48, 8, and 14 
patients, respectively. Six patients did not receive local ther-
apy after chemotherapy due to refusal, progression, or toxi-
city of chemotherapy (Fig. 1). Among the patients who
underwent combined surgery with RT in localized disease
(n=33), 32 patients received postoperative RT and one patient
received preoperative RT (Fig. 1). Among the patients who
underwent surgery without RT (n=37), seven patients
(18.9%) received incomplete resections. However, 15 patients
(46 9%) among those treated with postoperative RT (n=32)
received incomplete resections. Surgical resection without
postoperative RT was applied more in patients with tumors
in extremities (13/23, 56.5%) than in those with tumors in
spine or paravertebral area (3/13, 23.1%). Among the 32 
patients with large tumors (! 8 cm), 8, 12, and 7 patients 
underwent surgery, combined surgery and RT, and RT for
local treatment, respectively. Five patients with tumors ! 8
cm did not receive local therapy due to progression, treat-
ment refusal, or toxicity.
Forty-eight patients received RT with or without surgery
for the local control (LC) of primary tumor. Those treated
with RT without surgery (n=15) largely consisted of ! 8-cm
tumor (n=8) and pelvic tumor (n=6). 
Clinical treatment volume (CTV) was defined as the
prechemotherapy tumor volume or postoperative tumor bed
plus margin, usually 1-3 cm [13,14]. Gross tumor volume
(GTV) was defined as postchemotherapy tumor volume.
Modification of CTV margin was allowed for tumors located
in epiphysis, spine, head and neck to avoid excessive radia-
tion. Among patients who received RT with field reduction,
GTV was irradiated with a reduced field with a median dose
of 54.0 Gy (range, 45.0 to 59.4 Gy) after irradiation of CTV
with median dose of 41.4 Gy (range, 30.6 to 50.4 Gy). For the
other patients who underwent RT without field reduction,
CTV was irradiated with median dose of 50.4 Gy (range, 40.0
to 66.6 Gy). One patient with a huge tumor involving ribs 
received 80 Gy to GTV and 50 Gy to CTV with intensity-
modulated RT technique, instead of surgical resection.
3. Analysis
Median follow-up was 43.8 months. The median follow-
up period for surviving patients was 60.7 months. Treatment
response of patients was evaluated at the end of local ther-
apy, 1 and 3 months after local therapy, and semiannually
thereafter. Follow-up assessment included CT or MRI of 
primary tumor. 
Progression was defined as clinical or radiographic incr-
ease in the size of primary or metastatic tumor or new 
appearance of metastatic lesion. Progression-free survival
(PFS) was defined as the time interval from date of histolog-
ical diagnosis to date of first event (relapse or progression or
death).
4. Statistics
PASW Statistics ver. 18.0  (SPSS Inc., Chicago, IL) was used
for statistical analysis. Chi-square test was used to evaluate
treatment and prognostic factors for LC. Survival and LC
rates were calculated using Kaplan-Meier estimation. The
log-rank test was used for group comparisons. A Cox 
proportional hazards model was used to clarify independent
predictive factor in multivariate analysis. Statistical signifi-
cance was defined as a p-value of < 0.05.
Localized ESFT (n=91)
Patients treated with
local treatment modalities (n=85)
Patients treated without
local treatment modalities (n=6)
Surgery
(n=37)
Surgery+RT
(n=33)
RT
(n=15)
Patients treated with
surgery±postoperative RT (n=69)
Preoperative RT+
complete resection (n=1)
R0 resection
(n=47)
R1 resection
(n=8)
R2 resection
(n=14)
Fig. 1.  Patient arrangement according to local treatment
methods. ESFT, Ewing sarcoma family tumors; RT, radio-
therapy.
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Results
1. Patterns of failure
During the follow-up period, 43 patients (47.3%) showed
recurrence or progressive disease: 12 patients with local 
failure (Table 2) and 39 patients with distant metastasis 
(8 patients experienced both local and distant failure). Five
patients who experienced local failure had large primary 
tumors (! 8 cm). Among these five patients with large 
tumors, one patient underwent surgical resection, and two 
patients underwent RT for local therapy. In addition, the
other two patients did not receive any local treatment due to
early progression. The common sites of local failure were
pelvis (n=3) and extremity (n=3). Frequent metastatic sites
were lung in 19 patients and bone in 13 patients. The rate of
distant metastasis was higher in patients with tumors prima-
rily located in spinal or paravertebral regions (7/13, 53.8%).
Among these 43 patients with progression, 26 patients died,
12 patients were alive with disease 7.3-62.4 months after 
diagnosis, and five patients were saved with surgical resec-
tion.
2. Local control
The primary tumors were not controlled in 12 patients
(Table 2) and 5-year actuarial LC rate was 85.1% (Fig. 2).
Poorer responders to chemotherapy tended to show shorter
LC (Table 2). LC was different according to application of
local treatment modalities (n=85, p=0.042) (Fig. 3). LC rate
was higher in patients with combined surgery and RT 
compared to those with RT alone (5-year LC 90.2% vs. 64.8%,
p=0.052). Subset analyses were performed in patients with
localized disease who received RT with or without surgery
(n=48). In patients with tumors ! 8 cm (n=20), combined RT
with surgery showed superior LC than RT without surgery
(p=0.033) (Fig. 4A). However, there was no statistical differ-
ence in LC between the two groups among patients with 
tumors < 8 cm (n=28, p=0.374) (Fig. 4B). 
On top of that, radiation dose did not affect LC. The dose-
response relationship (< 50 Gy vs. ! 50 Gy) for LC was not
observed in patients with postoperative RT or with definitive
RT without surgery (p=0.227 and p=0.180, respectively). 
Further subset analyses for LC and resection margin status
were performed to find the role of adjuvant RT in patients
who underwent surgery (n=69, among 70 patients who 
underwent surgery±RT, one patient who underwent preop-
erative RT and complete resection was excluded from the
analyses). Fig. 5A presents the LC according to adjuvant RT
in patients with incomplete resection (n=22, 8 patients with
R1 resection and 14 patients with R2 resection). Adjuvant RT
did not significantly improve the LC in cases with incom-
plete resection (p=0.254) (Fig. 5A), nor did adjuvant RT 
provide a significant benefit on LC in cases with complete
resection (n=47, p=0.241) (Fig. 5B).  
3. Survival
The 5-year overall survival (OS) and PFS were 60.5% 
(Fig. 2) and 58.2%, respectively. The 5-year PFS was different 
according to the application of local modality (n=85,
Table 2. Characteristics of 12 patients with local failure
Age (yr)/Gender Size (cm) Site Initial treatment modalities Resection RT dose (Gy) NAC response LC period (mo)
26/M 3 Spine S+RT+CT R1 50.4 Adjuvant 23
5/F 4 Chest wall CT+S R0 0 PR 22
29/F 5 Head CT+RT No 59.4 NR 11
43/F 5 Head CT+RT No 55.8 NR 16
7/M 6 Extremity S+CT R0 0 Adjuvant 28
8/M 7 Abdomen S+RT+CT R1 50.4 Adjuvant 31
27/M 7 Extremity CT+RT+S R1 50.4 PR 72
20/F 9 Pelvis CT+RT No 54 PR 22
26/M 10 Pelvis CT+RT No 66.6 NR 11
5/F 12 Pelvis CT No 0 PD 3
25/M 15 Abdomen CT+S R0 0 PD 2
38/M 20 Extremity CT No 0 PD 4
RT, radiotherapy; NAC, neoadjuvant chemotherapy; LC, local control; S, surgery; CT, chemotherapy; PR, partial response;
NR, no response; PD, progressive disease.
Cancer Res Treat. 2015;47(4):904-912
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p=0.007). The 5-year PFS was 55.9% in patients treated with
combined RT and surgery and 39.4% in those treated with
RT without surgery. 
4. Prognostic factors for survival 
Univariate analysis showed that prognostic factors for OS
were primary tumor size (p < 0.001) and surgical resection
(p < 0.001). Tumor location did not affect the survival 
outcome (extremity vs. nonextremity, p=0.597; spine/
paravertebral lesion vs. nonspine/paravertebral lesion,
p=0.902; and pelvis  vs.  nonpelvis, p=0.424). Multivariate
analysis showed that primary tumor size (p=0.001) and 
surgical resection (p=0.024) were independent prognostic
factors for OS (Table 3).
In the subset analysis with patients who received RT with
or without surgery (n=48), surgical resection did not signifi-
cantly improve OS (p=0.161) and PFS (p=0.068) compared to
RT without surgery. However, in patients with tumors ! 8
cm (n=20), RT combined with surgery showed superior PFS
to RT without surgery (p=0.016). 
5. Secondary malignancy and treatment-related toxicity
Two patients (2.2%) experienced secondary malignancies
after treatment. Acute myeloid leukemia and diffuse large 
B-cell lymphoma (DLBCL) each occurred in one patient, 
respectively. Thirty-eight patients expired during the follow-
up period. Among them, 33 deaths were associated with 
progression of ESFT. One death was related to uncontrolled
DLBCL. Three patients died due to peripheral blood stem
cell transplantation-related toxicities (sepsis). One death was
related to pneumonia. As for late complications, two cases of
limb shortage and one case of stress fracture in bone were
observed during the follow-up period.
Discussion
Local treatment for ESFT can be accomplished by surgery,
RT, or both. However, no randomized trials have compared
surgery and RT. Although the role of surgery is emphasized
in some studies [15,16], RT still plays an important role in 
patients who need functional preservation or who have 
unresectable tumors. Combined surgery and RT can be used
in cases with large tumors or with positive resection margins.
Several retrospective studies have suggested that surgery
yields better LC and survival than RT [15,16]. In the present
study, PFS was better in patients who received surgery than
in patients who did not. Especially in large-sized tumors 
(diameter, ! 8 cm), RT without surgery demonstrated inferior
LC (p=0.033) (Fig. 4A) and PFS (p=0.016) compared to com-
bined surgery with RT. However, direct comparison between
RT and surgery was difficult due to patient selection bias
[14]. The patients who received RT without surgery had
more unfavorable prognostic factors such as tumor location
or size, not amenable to resection. As in the current series,
many surgical series included patients with lower risks, such
as smaller tumors and tumors at dispensable bones [16,17],
and the advantage and disadvantages of surgery and RT are
different. Compared with RT, which can cause secondary
malignancy and bone growth disturbances in young chil-
dren, surgical resection could result in functional deficits or
adverse cosmetic effects. Therefore, surgery and RT are not
competitive modalities, but complimentary modalities in the
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management of ESFT. Proper combination of function-
preserving surgery and RT with optimized radiation volume
and dose is mandatory for local treatment of ESFT. The 
selection of local treatment modality should be based on not
only LC rate but also rehabilitation capacity and psycholog-
ical effect.
RT can be used as an alternative or adjuvant treatment
modality for surgery in ESFT. RT could be considered for
treatment of tumors located in the spine or paravertebral area
[18], where complete surgical resection is rarely possible.
Presently, combined RT and surgery are mainly performed
in patients with spine or paravertebral tumors. As a result,
compared to a previous report [19] that documented poor
treatment outcome in spine tumors, the current study
showed that OS of spine and paravertebral ESFT were simi-
lar to that of other locations (p=0.902), as shown in Table 3.
In addition, RT can be applied in cases of expected high 
morbidity after surgical resection such as tumors located in
weight-bearing bones or pelvis [20]. Functional impairment
in the case of shoulder joints or cosmetic adverse effects in
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and radiotherapy (RT) (n=12) and RT without surgery (n=8), and local control in localized tumors < 8 cm according to treat-
ment methods (B); comparison between combined surgery and RT (n=21) and RT without surgery (n=7).
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cases of head and neck tumor-related resection [21] could 
influence the preference of RT.
The primary tumor burden and location also affected the
treatment selections. Those who were treated with RT with-
out surgery mostly had large tumors (! 8 cm, 8/15, 53.3%)
and/or pelvic tumors (6/15, 40.0%). RT used for patients
with unfavorable risk factors resulted in worse outcome than
for patients who received surgery. Adequate combination of
RT and less-ablative surgery could help patients who are at
high risk for surgical morbidity or mortality (e.g., pelvis 
tumors) and improve treatment outcome. 
In the current study, patients with tumors exceeding 8 cm
showed poorer outcome. Although local failure rate was 
similar between small- and large-sized tumors (12.0% for 
< 8 cm vs. 15.2% for ! 8 cm), the distant failure rate was
higher in large-sized tumors (36.2% for < 8 cm vs. 54.5% for
! 8 cm). This means that patients with a large tumor have
greater possibility of systemic disease and poor response to
chemotherapy resulting in distant failure as well as local fail-
ure. 
The role of chemotherapy is robust in the management of
ESFT to eradicate systemic disease and to achieve LC. Effec-
tive systemic chemotherapy shrinks the tumor and facilitates
surgical resection, and eventually reduces radiation dose and
volume or even omits RT. Most of the local failures in this
study showed poor response to chemotherapy. Therefore, 
response to chemotherapy is a strong prognostic factor [22].
Although chemotherapy with etoposide and/or ifos-
famide improves survival [2], distant metastases are still 
the main cause of treatment failure [23] and a more effective
systemic treatment modality is needed. High-dose
chemotherapy with peripheral blood stem cell transplanta-
tion has been tried for consolidation therapy or salvage ther-
apy. However, it was not as effective [24]. 
Secondary malignancy after alkylating agents is another
concern. According to an Italian sarcoma group experience
[8], 2.8% of patients experienced secondary malignancies and
radiation-induced osteosarcomas were the most common
secondary malignancy. Dunst et al. [25] reported a 4.7% 
cumulative incidence of secondary malignancy after 15 years
in patients with Ewing’s sarcoma using data in the CESS-81
and CESS-86. Two patients experienced secondary malignan-
cies (2.2%). There was no secondary solid tumor related to
radiation and two cases were hematologic malignancies. 
As for limitations, this study did not fully deal with 
the functional outcomes after RT. During follow-up, we 
observed two cases of limb shortage and one case of stress
fracture in bone. However, evaluation of functional outcome
demands close long-term follow-up with standardized eval-
uation tools and a multidisciplinary team approach. Mini-
mizing late complications is as important as maximizing
treatment efficacy. Further studies focused on functional 
Table 3. Univariate and multivariate analysis for overall survival (n=91)
Factor No. (%) Univariate analysis Multivariate analysis
5-Year (%) p-value HR (95% CI) p-value
Age (yr) 0.233 - -
< 14 28 (30.8) 75.2
! 14 63 (69.2) 54.0
Gender 0.885 - -
Male 48 (55.0) 65.3
Female 43 (45.0) 56.1
Tumor size (cm) < 0.001 2.948 (1.522-5.711) 0.001
< 8 58 (63.7) 74.2
! 8 33 (36.3) 34.4
Tumor location 0.902 - -
Spine or paravertebral lesions 13 (14.3) 66.7
Others 78 (85.7) 59.3
Surgery < 0.001 0.450 (0.224-0.902) 0.024
Resection 70 (76.9) 64.6
No resection 21 (23.1) 45.4
RT 0.188 - -
RT 48 (52.7) 52.8
No RT 43 (47.3) 68.9
HR, hazard ratio; CI, confidence interval; RT, radiotherapy.
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